Literature DB >> 22516762

Is travel-time to a specialist centre a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection?

Thomas Astell-Burt1, Robin Flowerdew, Paul Boyle, John Dillon.   

Abstract

Little is known about why many people diagnosed with hepatitis C virus (HCV) infection fail to reach and stay within specialist care services. We used a Geographic Information System and logit regression to investigate whether travel-time to a specialist centre was associated with an increased likelihood of non-referral, non-attendance and loss to follow-up among persons diagnosed with HCV between 1991 and 2003 in Tayside, Scotland (UK). Information was available on referral to, and utilisation of, the single HCV specialist centre in Tayside between 1991 and 2006. Longer travel-time to a specialist centre was associated with an increased likelihood of non-referral to a specialist centre following diagnosis (Odds Ratio: 1.25, 95% Confidence Interval: 1.09, 1.44). Patients living further from an HCV specialist centre were less likely to be referred to it for treatment that could cure their HCV infection. Neither a history of intravenous drug use (IDU), nor area deprivation predicted non-referral. Subsequent to referral, travel-time to a specialist centre was not associated with either non-attendance (0.83 (0.56, 1.21)) or loss to follow-up (0.98 (0.78, 1.22)), although a history of IDU was a strong predictor of both non-attendance and loss to follow-up. Non-attendance was less likely among older patients, while loss to follow-up was more common among those living in deprived areas. Once referred, patients appear able to cope with stress and financial cost of long and frequent journeys to hospital. However, as rates of referral improve from more geographically remote areas, long travel-times to an HCV specialist centre may become an important factor determining future utilisation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22516762     DOI: 10.1016/j.socscimed.2012.02.046

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  9 in total

1.  Awareness of biologically confirmed HCV among a community residing sample of drug users in Baltimore City.

Authors:  Nicole Ennis Whitehead; Lauren E Hearn; Michael Marsiske; Maria R Kahn; William W Latimer
Journal:  J Community Health       Date:  2014-06

2.  Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program.

Authors:  Stacey B Trooskin; Joanna Poceta; Caitlin M Towey; Annajane Yolken; Jennifer S Rose; Najia L Luqman; Ta-Wanda L Preston; Philip A Chan; Curt Beckwith; Sophie C Feller; Hwajin Lee; Amy S Nunn
Journal:  J Gen Intern Med       Date:  2015-02-14       Impact factor: 5.128

3.  Facilitating treatment of HCV in primary care in regional Australia: closing the access gap.

Authors:  Lauren White; Ali Azzam; Lauren Burrage; Clare Orme; Barbara Kay; Sarah Higgins; Simone Kaye; Andrew Sloss; Jennifer Broom; Nicola Weston; Jonathan Mitchell; James O'Beirne
Journal:  Frontline Gastroenterol       Date:  2018-10-24

4.  Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons.

Authors:  Sabrina A Assoumou; Abriana Tasillo; Claudia Vellozzi; Golnaz Eftekhari Yazdi; Jianing Wang; Shayla Nolen; Liesl Hagan; William Thompson; Liisa M Randall; Lara Strick; Joshua A Salomon; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 20.999

5.  Hepatitis C among blood donors: cascade of care and predictors of loss to follow-up.

Authors:  Soraia Mafra Machado; Cesar de Almeida; João Renato Rebello Pinho; Fernanda de Mello Malta; Ligia Capuani; Aléia Faustina Campos; Fatima Regina Marques Abreu; Ana Catharina de Seixas Santos Nastri; Rúbia Anita Ferraz Santana; Ester Cerdeira Sabino; Maria Cássia Mendes-Correa
Journal:  Rev Saude Publica       Date:  2017-04-27       Impact factor: 2.106

6.  Associations between access to healthcare, environmental quality, and end-stage renal disease survival time: Proportional-hazards models of over 1,000,000 people over 14 years.

Authors:  Marissa B Kosnik; David M Reif; Danelle T Lobdell; Thomas Astell-Burt; Xiaoqi Feng; John D Hader; Jane A Hoppin
Journal:  PLoS One       Date:  2019-03-21       Impact factor: 3.240

7.  Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model.

Authors:  Edward R Cachay; Lucas Hill; Craig Ballard; Bradford Colwell; Francesca Torriani; David Wyles; William C Mathews
Journal:  AIDS Res Ther       Date:  2013-03-28       Impact factor: 2.250

8.  The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care.

Authors:  Edward R Cachay; Lucas Hill; David Wyles; Bradford Colwell; Craig Ballard; Francesca Torriani; William C Mathews
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

9.  The balancing perspective of hard-to-reach hepatitis C patients who were lost to follow-up: A qualitative study.

Authors:  Patricia A M Kracht; Joop E Arends; Andy I M Hoepelman; Sigrid C J M Vervoort
Journal:  PLoS One       Date:  2020-04-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.